HomeCompareATEPF vs ABBV

ATEPF vs ABBV: Dividend Comparison 2026

ATEPF yields 363.83% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATEPF wins by $5766.01M in total portfolio value
10 years
ATEPF
ATEPF
● Live price
363.83%
Share price
$0.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5766.11M
Annual income
$3,742,597,980.41
Full ATEPF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ATEPF vs ABBV

📍 ATEPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATEPFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATEPF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATEPF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATEPF
Annual income on $10K today (after 15% tax)
$30,925.96/yr
After 10yr DRIP, annual income (after tax)
$3,181,208,283.35/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ATEPF beats the other by $3,181,187,227.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATEPF + ABBV for your $10,000?

ATEPF: 50%ABBV: 50%
100% ABBV50/50100% ATEPF
Portfolio after 10yr
$2883.11M
Annual income
$1,871,311,376.08/yr
Blended yield
64.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ATEPF
No analyst data
Altman Z
236.5
Piotroski
0/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATEPF buys
0
ABBV buys
0
No recent congressional trades found for ATEPF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATEPFABBV
Forward yield363.83%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$5766.11M$102.3K
Annual income after 10y$3,742,597,980.41$24,771.77
Total dividends collected$5574.88M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ATEPF vs ABBV ($10,000, DRIP)

YearATEPF PortfolioATEPF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$47,083$36,383.48$11,550$430.00+$35.5KATEPF
2$210,478$160,099.16$13,472$627.96+$197.0KATEPF
3$894,086$668,874.15$15,906$926.08+$878.2KATEPF
4$3,612,086$2,655,414.27$19,071$1,382.55+$3.59MATEPF
5$13,890,923$10,025,990.33$23,302$2,095.81+$13.87MATEPF
6$50,897,619$36,034,331.38$29,150$3,237.93+$50.87MATEPF
7$177,855,877$123,395,424.73$37,536$5,121.41+$177.82MATEPF
8$593,288,147$402,982,359.06$50,079$8,338.38+$593.24MATEPF
9$1,891,136,685$1,256,318,367.62$69,753$14,065.80+$1891.07MATEPF
10$5,766,114,234$3,742,597,980.41$102,337$24,771.77+$5766.01MATEPF

ATEPF vs ABBV: Complete Analysis 2026

ATEPFStock

Astra Exploration Inc., an exploration company, engages in the acquisition, exploration, and development of epithermal gold-silver properties in Chile. It holds 80% interest in the Pampa Paciencia project located in the Antofagasta Region of Chile. The company is headquartered in Vancouver, Canada.

Full ATEPF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ATEPF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATEPF vs SCHDATEPF vs JEPIATEPF vs OATEPF vs KOATEPF vs MAINATEPF vs JNJATEPF vs MRKATEPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.